Why the study?
Clinical characteristics, risk profile, and outcomes of portopulmonary hypertension in the current era of pulmonary artery targeted therapies without liver transplantation are not well known.
Cohort (n=160)
No
p-value: p=<0.001
In patients with portopulmonary hypertension who do not undergo liver transplantation, long-term survival remains poor and is significantly driven by the severity of underlying liver disease.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted a cohort in Portopulmonary Hypertension (PoPH) (n=160). Portopulmonary Hypertension without liver transplantation was evaluated on Overall survival (p=<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: